8/14/2019 Small Animal/Exotics

1/2

8/14/2019 Small Animal/Exotics

2/2

DOSAGE AND ADMINISTRATIONThe recommended dose in dogs is 10 to 15 mg/kg orally

once daily. Once a satisfactory clinical response is achieved,the dose should be adjusted to the lowest effective dose forlifetime management of osteoarthritis.

PREPARATIONSEtoGesic (Fort Dodge, Ft. Dodge, IA) is available in

150- and 300-mg scored tablets and comes in bottles of100 and 250 tablets. The average wholesale price per tabletis $0.30 for 300-mg tablets and $0.24 for 150-mg tablets.

The aqueous stability of this drug in suspension has notbeen investigated; therefore compounding this drug into asuspension is not recommended.

Compendium June 1999 20TH ANNIVERSARY Small Animal/Exotics

Client Counseling Information

I Etodolac is used to relieve pain and inflammationin dogs.

I Etodolac is a very safe drug; however, some dogs

may have adverse reactions. If your dog showssigns of vomiting, diarrhea, or inappetence or ifyou notice blood in its stool, you shouldimmediately stop giving the drug and contact yourveterinarian.

I Tell your veterinarian if your dog is taking anymedications other than etodolac. You should notgive your dog any other pain medications, such asaspirin, while it is taking etodolac.

STORAGE AND HANDLINGEtodolac tablets should be stored at a controlled room

temperature (15C to 30C [59F to 86F]).

REFERENCES1. Humber LG: Etodolac: The chemistry, pharmacology, metabolic dis-

position and clinical profile of a novel anti-inflammatory pyrano-carboxylic acid. Med Res Rev7:1, 1987.

2. Humber LG: On the classification of NSAIDs. Drug News Perspect5:102103, 1992.

3. Gervais G, Martel RR, Skamene E: The effect of the nonsteroidalanti-inflammatory drug etodolac on macrophage migration in vitroand in vivo.J Imunopharmacol6:205214, 1984.

4. Budsberg SC, Johnston SA, Schwarz PD, et al: Efficacy of etodolacfor the treatment of osteoarthritis of the hip joints in dogs. JAVMA214(2):206210, 1999.

5. Kraml M, Cosyns L, Hicks DR, et al: Bioavailability studies withetodolac in dogs and man. Biopharm Drug Dispos5:6374, 1984.

6. Cayen MN, Kraml M, Ferdinandi ES, et al: The metabolic disposi-tion of etodolac in rats, dogs and man. Drug Metabol Rev 12:363

377, 1981.7. Freedom of Information Summary: NADA141108 (original), Eto-Gesic for Dogs (etodolac), 1998.

8. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of ac-

tion for aspirin-like drugs. Nat New Biol231:232235, 1971.

9. Fry SW, Seeff LB: Hepatotoxicity of analgesics and anti-inflammato-

ry agents. Gastroenterol Clin North Am24:875905, 1995.10. Boldy DA, Hale KA, Val JA: Etodolac overdose. Human Toxicol

7(2):203204, 1988.11. Kastrup C (ed): Drug Facts and Comparisons. St Louis, MO, Facts and

Comparisons, 1998, p 251e.

About the AuthorMs. Davidson is the Director of Pharmacy, College ofVeterinary Medicine, North Carolina State Universi-ty, Raleigh, North Carolina.